Evaluation of Fibroblastic Activation Protein Inhibitors (FAPI) as a novel radiopharmaceutical targeting cancer-associated fibroblasts for the diagnosis and treatment of patients with Cancer of Unknown Primary: the FAPI-CUP trial

Grant number: 1200038 | Funding period: 2020 - 2025

Active